India Pharma Outlook Team | Tuesday, 26 May 2026
.jpeg "Moderna & Merck Combo Cuts Melanoma Spread Risk by 59% in 5-Year Study")
Moderna and Merck’s combination therapy for melanoma is showing strong long-term promise, with new mid-stage trial data indicating a 59 percent reduction in the risk of cancer spreading after five years.
The study evaluated Moderna’s personalized cancer vaccine, intismeran autogene, alongside Merck’s widely used immunotherapy Keytruda in patients who had undergone surgery for skin cancer.
The trial, conducted between 2019 and 2021 with 157 patients, aimed to assess whether the combination could prevent recurrence. Results show a clear advantage: overall survival reached 92.2 percent in the combination arm compared to 71.3 percent for patients treated with Keytruda alone. Earlier data had already demonstrated a 49 percent reduction in recurrence or death at the five-year mark, reinforcing the consistency of outcomes over time.
The therapy works by leveraging a patient-specific approach. Intismeran autogene is designed using the genetic signature of an individual’s tumor, enabling the immune system to better recognize and attack cancer cells. This represents a shift from conventional one-size-fits-all treatments to highly targeted, precision oncology solutions.
A late-stage trial is currently underway to evaluate the combination as a first-line treatment for melanoma. Beyond skin cancer, the vaccine is also being tested across other tumor types, including lung cancer, to explore its broader potential in preventing disease recurrence.
Safety data from the study remained consistent with previous analysis. Seven patients in each treatment group died during follow-up, mostly due to cancer progression, indicating no additional safety concerns linked to the combination therapy.
Also Read: Robotic Gynae Oncology Ecosystem Improves Women's Cancer Care India
Globally, skin cancer particularly melanoma continues to be a major public health concern, with incidence rates rising steadily across North America, Europe, and Australia. According to recent estimates, over 325,000 new melanoma cases are diagnosed worldwide each year, with the United States alone expected to report around 234,000 new cases in 2026. This rise is largely driven by higher UV exposure, aging populations, and improved detection rates.
Over the past decade, however, treatment outcomes have improved significantly. The introduction of immunotherapies such as pembrolizumab (Keytruda) and nivolumab has transformed melanoma care. Five-year survival rates for advanced melanoma, which were once below 30 percent, have now improved to nearly 50–55 percent in many cases, particularly when treated early and with combination therapies. As a result, melanoma is increasingly being managed as a chronic condition rather than a terminal illness in certain patient groups.
Despite these advances, recurrence remains a critical global challenge. Studies suggest that 30–50 percent of high-risk melanoma patients may experience relapse even after surgery and standard therapy. This underscores the need for more durable, long-term solutions. Next-generation approaches like personalized cancer vaccines, including Moderna’s intismeran autogene, are gaining attention for their ability to train the immune system to recognize tumor-specific mutations and prevent recurrence at a molecular level.
From an India perspective, the landscape is notably different but evolving. Melanoma accounts for less than 1–2 percent of all skin cancers in India, and overall incidence remains significantly lower than in Western countries. However, this lower prevalence has led to gaps in awareness and screening. As a result, a large proportion of cases in India are diagnosed at advanced stages, where five-year survival rates can drop below 20–30 percent, compared to over 90 percent in early-stage melanoma globally.
At the same time, India’s overall cancer burden is rising sharply. The country reported over 1.4 million new cancer cases annually, with projections indicating a steady increase driven by aging demographics, urbanization, and lifestyle-related risk factors. While skin cancer is not among the top contributors, the oncology ecosystem is undergoing rapid transformation. Immunotherapy adoption is growing at 15–20 percent annually in leading urban centers, alongside increasing use of targeted therapies and precision medicine.
This shift indicates that while melanoma may not yet be a major public health burden in India, the infrastructure and clinical readiness for advanced cancer care are steadily improving—creating a pathway for next-generation therapies to enter the market in the coming years.
The ongoing late-stage trial will be a key milestone in determining whether this combination can move into standard first-line therapy. If successful, it could redefine melanoma treatment protocols globally. Moreover, personalized cancer vaccines are anticipated to gain momentum across multiple cancer types, shifting oncology toward precision-driven, immune-based interventions.
Pharmaceutical companies are also likely to invest further in mRNA platforms, combination therapies, and biomarker-driven drug development. Regulatory pathways may evolve to accommodate faster approvals for such targeted therapies, especially where strong survival benefits are demonstrated.
Moderna is a biotechnology company focused on mRNA-based medicines and vaccines. It gained global prominence with its COVID-19 vaccine and is now expanding into oncology, rare diseases, and personalized therapeutics, leveraging its mRNA platform for targeted treatment innovation.
Merck is a global pharmaceutical leader known for its immunotherapy drug Keytruda, widely used in cancer treatment. The company focuses on oncology, vaccines, and infectious diseases, with a strong pipeline and global presence in developing innovative, life-saving therapies.
.jpg)
.jpg)
